m6A Monoklonaler Antikörper

m6A Monoklonal Antikörper für IF-P

Wirt / Isotyp

Maus / IgG3

Getestete Reaktivität

m6A

Anwendung

IF-P

Konjugation

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

1D5E10

Kat-Nr. : CL488-68055

Synonyme

6-N-Methyladenoside, N6-methyladenosine

---

• 

  IF Staining of mouse testis using CL488-68055

  Immunofluorescent analysis of (4% PFA) fixed paraffin-embedded mouse testis tissue using CoraLite® Plus 488 m6A antibody (CL488-68055, Clone: 1D5E10 ) at dilution of 1:200. Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF-P: Maushodengewebe

Empfohlene Verdünnung

• Immunfluoreszenz (IF)-P: IF-P : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL488-68055 bindet in IF-P m6A und zeigt Reaktivität mit m6A

• Getestete Reaktivität: m6A
• Wirt / Isotyp: Maus / IgG3
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: Peptid
• Vollständiger Name: m6A
• GenBank-Zugangsnummer: m6A
• Konjugation: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 493 nm / 522 nm
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

m6A (N6-methyladenosine) is the most abundant internal modification in mammalian mRNA. This modification is installed by the m6A methyltransferases or termed "writers"such as METTL3 and METTL14, and can be reversed by demethylases that serve as "erasers" such as FTO and ALKBH5. The stability of m6A-modified mRNA is regulated by m6A reader protein YTHDFs, which recognizes m6A and reduces the stability of target transcripts. m6A modification and its regulatory proteins play critical roles in cancer pathogenesis and progression. m6A modification is also invovled in viruses life cycles, suggesting that drugs targets to m6A pathway could be used for antiviral thereapy.